MVMarco Van Vulpen

Marco Van Vulpen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marco Van Vulpen has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 December 2015
      • Vol. 35  (12) , 6773-9

    Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.

    by Leonie Alberts, Sherif Y El Sharouni, Frederik N Hofman, Bart P Van Putte, Ellen Tromp, Marco Van Vulpen, Elisabeth A Kastelijn, Franz M N H Schramel

    To evaluate changes in pulmonary function tests (PFTs) at different follow-up durations after stereotactic body radiotherapy (SBRT) and surgery in stage I and II non-small-cell lung cancer (NSCLC). Differences between pre-treatment- and follow-up PFTs were analyzed in 93 patients treated with surgery and 30 patients treated with SBRT for NSCLC. Follow-up durations were categorized into: early (0-9 months), middle (10-21 months) and late (≥22 months). Wilcoxon signed-rank test was used to analyze differences between pre-treatment and follow-up PFTs. Forced expiratory volume in one second, forced vital capacity and diffusion capacity for carbon monoxide corrected for the actual hemoglobin level significantly diminished after surgery for all follow-up durations: 11-17% of predicted values. After SBRT, PFTs remained stable, but a declining trend of 6% (p=0.1) was observed after 22 months. SBRT might lead to less treatment-related toxicity measured by PFTs than surgery in both the short and long term.


  • Dosimetric feasibility of MRI-guided external beam radiotherapy of the kidney

    by Mette K Stam, Marco Van Vulpen, Maurits M Barendrecht, Bernard A Zonnenberg, Sjoerd P M Crijns, Jan J W Lagendijk, Bas W Raaymakers

    At our institution a treatment for kidney tumours with an MRI-Linac is under development. In order to set inclusion criteria for this treatment the anatomical eligibility criteria and the influence of the motion compensation strategy on the delivered dose should be known. Twenty patients with a renal lesion underwent an MR-scan to image the kidney. Static treatment plans were made and the doses to the organs at risk were evaluated. Furthermore, to calculate the influence of remnant motion in a gated treatment, a convolution of the static dose plan with the residual motion in a gating window was done. For ten patients (50%) a static plan within the dose constraints could be obtained. For all patients where the kidney constraint was obeyed in the static plan, the dose to the gross tumour volume (GTV) and the ipsilateral kidney remained within limits for residual motion in a gating window up to and including 12 mm. For four patients (20%) no static plan without violation of the constraint to the ipsilateral kidney could be made. One of these patients had a tumour of 73 mm in the upper pole and the other patients had a tumour of at least 30 mm in the mid pole. In 6 patients (30%), where the bowels were within the planning target volume, the maximum dose to the bowels was above the limit used. Patient specific assessment might degrade this violation. For tumours smaller than 30 mm a clinically acceptable plan could be created. For other patients the feasibility depends on the geometry of the GTV and kidney. Neither the GTV coverage nor the ipsilateral kidney dose is compromised by breathing motion for gating with a gating window up to and including 12 mm.


  • The feasibility of using a conventional flexible RF coil for an online MR-guided radiotherapy treatment

    by Stan J Hoogcarspel, Sjoerd P M Crijns, Jan J W Lagendijk, Marco van Vulpen, Bas W Raaymakers

    The purpose of this paper is to evaluate the impact of a flexible radiofrequency coil on the treatment delivery of an online MR-guided radiotherapy treatment. For this study, we used a Synergy MR body coil (Philips, Best) in combination with the current MRL prototype of the UMC Utrecht. The compatibility of the coil is evaluated in two steps. First, we evaluated the dosimetric impact of the MR coil on both a simple and a complex irradiation strategy for treating spinal bone metastases. This tumor site will likely be chosen for the first in-man treatments with the UMC Utrecht MRL system. Second, we investigated the impact of the treatment beam on the MRI performance of the body coil. In case a single posterior-anterior rectangular field was applied, dose to the target volume was underestimated up to 2.2% as a result of beam attenuation in the MR coil. This underestimation however, decreased to 1% when a stereotactic treatment strategy was employed. The presence of the MR coil in or near the distal site of the treatment beam decreased the exit dose when a magnetic field was present. The MRI performance of the coil was unaffected as the result of the radiation. It is feasible to use the Synergy MR body coil for an online MR-guided radiotherapy treatment without any modification to the coil or attenuation correction methods in the planning stage. The effect of the MRI coil on the dose delivery is minimal and there is no effect of the treatment beam on the SNR of the acquired MRI data.


  • Open Access

    Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results

    by M. Van Vulpen, A.A.C. De Leeuw, B.W. Raaymakers, R.J.A. Van Moorselaar, P. Hofman, J.J.W. Lagendijk, J.J. Battermann

    OBJECTIVE: To report an interim clinical evaluation of combined external beam irradiation (EBRT) and interstitial or regional hyperthermia in the treatment of locally advanced prostate cancer. PATIENTS AND METHODS: From 1997 to 2001, 26 patients with T3‐4/NX/0M0 prostate carcinoma were treated with a combination of conformal EBRT and hyperthermia. Fourteen patients received five weekly regional hyperthermia treatments within an optimization (phase II) study, using the coaxial transverse electrical magnetic system. Twelve patients received one interstitial hyperthermia treatment within a feasibility study (phase I), using the multi‐electrode current source system. Irradiation was delivered using a conformal three‐field technique, administering 70 Gy in 2‐Gy fractions in 7 weeks. RESULTS: The mean initial prostate‐specific antigen level was 26 ng/mL. Three patients had a T4 and 23 a T3 tumour; the tumours were classified as well (four), moderately (16) and poorly (six) differentiated. The mean follow‐up was 36 months. In the combined treatments there was no toxicity of more than grade 2. In regional hyperthermia the mean index temperature (T 90 and T 50 , i.e. exceeded by 90% and 50% of the measurements) was 40.2 °C and 40.8 °C, and for interstitial hyperthermia 39.4 °C and 41.8 °C, respectively. All patients survived; seven patients had a biochemical relapse (27%), three in the regional and four in the interstitial group. The actuarial probability of freedom from biochemical relapse was 70% at 36 months for all patients together, 79% for regional and 57% for interstitial. No factors were found that could be used to predict relapse. CONCLUSIONS: The clinical outcome in these patients with advanced localized prostate cancer seems to compare favourably with most series using irradiation alone, and the treatment caused no severe complications.


  • Comparison of intra-luminal versus intra-tumoural temperature measurements in patients with locally advanced prostate cancer treated with the coaxial TEM system: report of a feasibility study

    by M. Van Vulpen, A. A. C. De Leeuw, J. B. Van De Kamer, H. Kroeze, T. A. Boon, C. C. Wárlám-Rodenhuis, J. J. W. Lagendijk, J. J. Battermann

    A study was performed on regional hyperthermia for patients with locally advanced prostate carcinoma. The primary objective was to analyse the thermometry data with an emphasis on the possibility of replacing invasive thermometry by tumour-related intra-luminal thermometry. Fourteen patients were treated with a combination of conformal external beam radiotherapy (70 Gy) and hyperthermia. Hyperthermia was delivered using the Coaxial TEM system, one treatment per week, to a total of five treatments. Thermometry was performed in bladder, urethra, rectum and esophagus. Invasive thermometry in the prostate was carried out during one or two treatments for each patient by placing transperineally a central and a peripheral catheter. Heterogeneous temperature distributions were measured in the prostate. The mean average invasive temperature range was 1.1 degrees C. Due to the temperature heterogeneity and a limited number of thermometry sensors (mean 7, range 2-13), large variability between treatments and patients existed regarding achieved temperatures and dose. The mean invasive T90 was 40.2 +/- 0.6 degrees C and T50 was 40.8 +/- 0.6 degrees C. The mean Cum min T90>40.5 degrees C per treatment was 22 (range 0-50). Importantly, intra-luminal temperatures did not reliably predict invasively measured temperatures. Invasive thermometry, therefore, remains compulsory to calculate a thermal dose for an individual patient. Changes in temperature during treatment, measured by the urethral sensors, corresponded well with changes in temperature measured by the individual invasive sensors. Similar comparison of rectal temperature changes with intra-prostatic temperature changes was not as predictive. The similarity in temperature changes between the urethral and interstial sites, suggests that urethral temperatures are sufficient for treatment optimization. The SAR profile did not correspond with the temperature profile indicating heterogeneous perfusion. Although regional hyperthermia in combination with external beam radiotherapy for locally advanced prostate carcinoma is clinically feasible, the question on the importance of invasive thermometry remains.


  • A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia

    by M. Van Vulpen, J. R. J. De Leeuw, M. P. R. Van Gellekom, J. Van Der Hoeven, A. De Graeff, R. J. A. Van Moorselaar, I. Van Der Tweel, P. Hofman, J. J. W. Lagendijk, J. J. Battermann

    The aim of this prospective study was to describe quality of life (QoL) in patients with locally advanced prostate carcinoma treated with conventional radiotherapy and to evaluate the influence of adding regional or interstitial hyperthermia. All patients were irradiated using a CT-planned conventional three field technique, administering 70 Gy to prostate and vesicles. In two different phase I studies, hyperthermia was added to the radiotherapy. Twelve patients were treated with one interstitial hyperthermia treatment, lasting 60 min. Fourteen patients have been treated with five regional hyperthermia treatments, lasting 75 min each. In both hyperthermia studies, the body, bladder and rectum temperatures remained below safety limits. Patients treated with radiotherapy alone (n = 58) or combined with regional (n = 8) or interstitial hyperthermia (n = 12) completed the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (C30 + 3), the EORTC prostate cancer module (PR25) and the Rand 36 health survey before treatment and 1 and 6 months after completion of treatment. Analysis of Variance (ANOVA) for repeated measurements has been performed to describe the data. All patient groups were comparable concerning patient characteristics. No significant interaction or difference in QoL has been noticed between the two hyperthermia patient groups and the patient group without hyperthermia. Therefore, all groups were analysed together (n = 78) to detect QoL changes in time. A deterioration of QoL has been measured from baseline to 1 month after treatment. Fatigue, pain, urinary symptoms, bowel symptoms and financial difficulties increased significantly. Social, physical and role functioning worsened significantly. No differences in QoL were measured 6 months after treatment compared to the baseline measurement, except for a decrease in sexual activity. After radiotherapy with or without hyperthermia only a temporary deterioration of QoL occurs, concerning social, psychological and disease related symptoms. Additional hyperthermia does not seem to decrease QoL.


  • Prostate perfusion in patients with locally advanced prostate carcinoma treated with different hyperthermia techniques.

    by Marco Van Vulpen, Bas W Raaymakers, Astrid A C De Leeuw, Jeroen B Van De Kamer, R Jeroen A Van Moorselaar, Monique G G Hobbelink, Jan J Battermann, Jan J W Lagendijk

    We determined prostate perfusion in 18 patients with locally advanced prostate carcinoma treated with a combination of external beam irradiation and regional (10) or interstitial (8) hyperthermia. Perfusion values were calculated from temperature elevations due to constant applied power and from transient temperature measurements after a change in applied power. Student's t test was used for comparing perfusion values with time and in the 2 groups. At the start of regional hyperthermia treatment mean estimated perfusion plus or minus standard deviation was 10 +/- 8 ml./100 gm. per minute. At the end of treatment mean perfusion was increased to 14 +/- 2 ml./100 gm. per minute (p <0.01). Achieved thermal parameters were a mean temperature of at least 40.3C +/- 0.6C in 90% of the prostate, 40.9C +/- 0.6C in 50% and a mean maximum temperature of 41.6C +/- 0.6C. At the end of interstitial hyperthermia treatment estimated mean perfusion was 47 +/- 5 ml./100 gm. per minute, which was significantly different compared with the end of regional hyperthermia (p < 0(-7) ). Mean temperature was at least 39.4C +/- 0.9C in 90% of the prostate and 41.8C +/- 1.6C in 50%, while mean maximum temperature was 53.1C +/- 6.3C. Systemic temperature increased during regional hyperthermia up to 38.6C, whereas during interstitial hyperthermia body temperature was not elevated. During interstitial hyperthermia perfusion values are higher than during regional hyperthermia. Hyperthermia causes increased prostate perfusion.


  • Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review)

    by Marco van Vulpen, Henk B. Kal, Martin J.B. Taphoorn, Sherif Y. El Sharouni

    The brain requires a stable internal environment, which is established by the integrity of the blood-brain barrier (BBB). The efficacy of chemotherapeutics in the treatment of brain malignancies is often hampered by the presence of the BBB. BBB disruption can be performed either by osmotic disruption, bradykinin or irradiation. Radiotherapy with doses of 20 to 30 Gy with fraction size of 2 Gy may be used to increase the permeability of the BBB. These radiation doses by themselves will not give rise to serious side effects or long-term complications. Disruption of the BBB by radiotherapy might have implications in the treatment of primary brain tumors, cerebral metastases, and prophylactic cranial irradiation in small cell lung cancer since irradiation will cause cell kill and may enhance the effect of chemotherapy. We present a review on the effects of irradiation on the BBB and subsequently discuss the potential value for therapeutic applications.


  • Three-dimensional controlled interstitial hyperthermia combined with radiotherapy for locally advanced prostate carcinoma—a feasibility study

    by Marco van Vulpen, Bas W Raaymakers, Jan J.W Lagendijk, Johan Crezee, Astrid A.C de Leeuw, Jeroen R.A van Moorselaar, Cornelis M Ligtvoet, Jan J Battermann